Lutetium dotatate was approved by FDA in 2018 for
Lutetium (Lu 177) dotatate a radiolabeled somatostatin analogue, for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumours in adults.
TB
Neuroendocrine tumours
Crohn's disease
Peptic ulcer
All India exam